Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) insider Boxer Capital Management, Llc sold 625,000 shares of Tango Therapeutics stock in a transaction on Monday, October 21st. The stock was sold at an average price of $7.05, for a total value of $4,406,250.00. Following the transaction, the insider now owns 7,573,642 shares in the company, valued at approximately $53,394,176.10. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Tango Therapeutics Stock Down 5.6 %
NASDAQ TNGX traded down $0.37 on Wednesday, reaching $6.27. The stock had a trading volume of 881,138 shares, compared to its average volume of 762,270. The stock has a fifty day moving average price of $8.85 and a two-hundred day moving average price of $8.49. Tango Therapeutics, Inc. has a 12-month low of $6.12 and a 12-month high of $13.01. The firm has a market capitalization of $669.92 million, a price-to-earnings ratio of -5.55 and a beta of 0.81.
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.10. Tango Therapeutics had a negative return on equity of 44.73% and a negative net margin of 274.04%. The firm had revenue of $19.88 million for the quarter, compared to the consensus estimate of $7.39 million. Sell-side analysts forecast that Tango Therapeutics, Inc. will post -1.27 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Report on Tango Therapeutics
Institutional Trading of Tango Therapeutics
Hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP grew its holdings in shares of Tango Therapeutics by 110.8% in the fourth quarter. Wellington Management Group LLP now owns 170,228 shares of the company’s stock valued at $1,685,000 after purchasing an additional 89,481 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Tango Therapeutics by 32.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company’s stock valued at $230,000 after buying an additional 7,128 shares during the period. SG Americas Securities LLC grew its stake in shares of Tango Therapeutics by 16.0% in the first quarter. SG Americas Securities LLC now owns 30,429 shares of the company’s stock worth $242,000 after acquiring an additional 4,203 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Tango Therapeutics during the first quarter worth $272,000. Finally, Vanguard Group Inc. increased its position in shares of Tango Therapeutics by 3.4% during the first quarter. Vanguard Group Inc. now owns 3,080,885 shares of the company’s stock worth $24,462,000 after acquiring an additional 101,673 shares during the period. Institutional investors and hedge funds own 78.99% of the company’s stock.
Tango Therapeutics Company Profile
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Read More
- Five stocks we like better than Tango Therapeutics
- How to Invest in Small Cap StocksĀ
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Why is the Ex-Dividend Date Significant to Investors?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What is a Special Dividend?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.